Clinical Trials Logo

Malignant Pleural Mesothelioma clinical trials

View clinical trials related to Malignant Pleural Mesothelioma.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 2

NCT ID: NCT00969098 Active, not recruiting - Clinical trials for Malignant Pleural Mesothelioma

Response Evaluation in Malignant Pleural Mesothelioma

Start date: June 2009
Phase: N/A
Study type: Observational

Recently, a few small trials have shown promising results on value of fluoro-2-deoxy-D-glucose and positron emission tomography imaging in response assessment in Malignant Pleural Mesothelioma. These studies considered different parameters in Positron Emission Tomography (PET) analysis, mainly the standardized uptake value and volume-based parameters such as total glycolytic volume.

NCT ID: NCT00886028 Active, not recruiting - Clinical trials for Malignant Pleural Mesothelioma

Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma

Start date: September 2006
Phase: Phase 2
Study type: Interventional

Liposomal doxorubicin consists on doxorubicin encapsulated in liposomes that are composed of phosphatidylcholine and cholesterol. Liposomal doxorubicin can extravasate into tumors with abnormal vascular endothelium but may not penetrate normal tissues lowering its toxicity and increasing its efficiency. Combining Liposomal doxorubicin with cisplatin could be an effective new chemotherapy treatment for malignant pleural mesothelioma . Hypothesis: Liposomal doxorubicin combined with cisplatin could increase response rates to chemotherapy, progression free survival and overall survival in patients with malignant pleural mesothelioma.

NCT ID: NCT00797719 Active, not recruiting - Clinical trials for Malignant Pleural Mesothelioma

Short Neoadjuvant Hemithoracic IMRT for MPM

Start date: October 2008
Phase: Phase 1/Phase 2
Study type: Interventional

Malignant pleural mesotheliomas (MPMs) are tumours associated with asbestos exposure involving the tissue lining surrounding the lung. Radiation therapy (RT) dramatically reduces the risk of tumour recurrence within the irradiated area (>90%). But patients continue to succumb to MPMs due to the tumour spreading outside the chest cavity. This may be due to tumour cells inadvertently contaminating areas outside the chest cavity during surgery. The study will look at whether giving a short intense course of chest radiation just prior to surgery will sterilized these tumour cells and thus, avoid or reduce contamination of the areas outside the chest cavity. The investigators hypothesize that short neoadjuvant (pre-operative) hemithoracic RT, followed by immediate planned extrapleural pneumonectomy (EPP) (+/- adjuvant chemotherapy) will reduce the risk of intra-operative seeding and reduce the incidence of distant metastatic disease.